Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein ...
... Drug Administration (FDA) granted orphan drug designation for the Company's T-lymphocyte product candidate activated against Epstein-Barr Virus (EBV-CTL) for the treatment of patients with EBV Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) ...
GlobeNewswire (press release) - Mon, 08 Feb 2016 04:56



Letter to the Editor
Rituximab (MabThera, Rituxan) in vivo mechanisms of action remain incompletely understood and could differ depending on the subtype of B-lymphoproliferative disorders. Rituximab has been shown to induce apoptosis, complement-mediated lysis, ...
Nature.com - Fri, 22 Jan 2016 06:15



Common variable immunodeficiency associated with microdeletion of chromosome ...
Common variable immunodeficiency (CVID) is a heterogeneous disorder of unknown etiology characterized by decreased immunoglobulin G (IgG) and additional Ig isotype(s) and impaired specific antibody responses; they often present with increased .... T ...
Nature.com - Fri, 22 Jan 2016 00:20



Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma ...
Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 2012; 18: 1611–1618. | Article | PubMed | CAS |; Wilcox RA, Feldman AL, ...
Nature.com - Mon, 01 Feb 2016 06:37



Iroquois Steeplechase names 75th anniversary event co-chair
He is a widely published author of more than 200 peer-reviewed publications, and is the editor-in-chief of the journal Pediatric Transplantation. In addition, he is co-editor of Pediatric Solid Organ Transplantation, Post-Transplant Lymphoproliferative ...
Franklin Home Page - Mon, 25 Jan 2016 12:03

Enzyme Proves Viable Drug Target for Deadly Epstein-Barr Virus Infections in ...
New research suggests that targeting a single enzyme could put the brakes on a lethal immune response triggered by Epstein-Barr virus (EBV) in patients with X-linked lymphoproliferative disease (XLP-1). The findings were reported in the Jan. 13, 2015 ...
Newswise (press release) - Mon, 11 Jan 2016 17:01

Enzyme Proves Viable Drug Target for Epstein-Barr Virus Infections in Duncan's ...
New research suggests that targeting a single enzyme could put the brakes on a lethal immune response triggered by Epstein-Barr virus (EBV) in patients with X-linked lymphoproliferative disease (XLP-1). The findings were reported in the Jan. 13, 2015 ...
Infection Control Today - Thu, 14 Jan 2016 07:56



miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell ...
Interestingly, we have observed lower expression of miR-23b in WM, an indolent lymphoproliferative disease with high Sp1 activity (Figure 2c). Importantly we observed further downregulation of miR-23b expression in MM cells following interaction with ...
Nature.com - Fri, 15 Jan 2016 06:29


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014